[go: up one dir, main page]

MX2016007128A - Compuestos del receptor 6 de quimiocina (ccr6). - Google Patents

Compuestos del receptor 6 de quimiocina (ccr6).

Info

Publication number
MX2016007128A
MX2016007128A MX2016007128A MX2016007128A MX2016007128A MX 2016007128 A MX2016007128 A MX 2016007128A MX 2016007128 A MX2016007128 A MX 2016007128A MX 2016007128 A MX2016007128 A MX 2016007128A MX 2016007128 A MX2016007128 A MX 2016007128A
Authority
MX
Mexico
Prior art keywords
compounds
formula
ccr6
useful
ccr6 compounds
Prior art date
Application number
MX2016007128A
Other languages
English (en)
Inventor
w lange Christopher
Reddy Leleti Manmohan
Li Yandong
Reddy Mali Venkat
Yang Ju
M Lui Rebecca
P Powers Jay
R Dragoli Dean
Malathong Viengkham
Tanaka Hiroko
Zhang Penglie
Dairaghi Daniel
Kalisiak Jarek
Tan Joanne
J Walters Matthew
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2016007128A publication Critical patent/MX2016007128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Se proporcionan compuestos de la fórmula (I) que son útiles en el tratamiento de enfermedades o condiciones moduladas al menos en parte por CCR6: (ver Fórmula).
MX2016007128A 2013-12-02 2014-12-02 Compuestos del receptor 6 de quimiocina (ccr6). MX2016007128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361910838P 2013-12-02 2013-12-02
PCT/US2014/068152 WO2015084842A1 (en) 2013-12-02 2014-12-02 Ccr6 compounds

Publications (1)

Publication Number Publication Date
MX2016007128A true MX2016007128A (es) 2016-08-11

Family

ID=53274030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007128A MX2016007128A (es) 2013-12-02 2014-12-02 Compuestos del receptor 6 de quimiocina (ccr6).

Country Status (13)

Country Link
US (4) US9340509B2 (es)
EP (1) EP3076968B1 (es)
JP (1) JP6563947B2 (es)
KR (1) KR102331833B1 (es)
CN (1) CN105960237B (es)
AU (1) AU2014360743C1 (es)
CA (1) CA2930148C (es)
EA (1) EA029826B1 (es)
ES (1) ES2735360T3 (es)
IL (1) IL245704B (es)
MX (1) MX2016007128A (es)
WO (1) WO2015084842A1 (es)
ZA (1) ZA201603167B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014360743C1 (en) 2013-12-02 2021-01-28 Chemocentryx, Inc. CCR6 compounds
RU2020106383A (ru) 2017-08-14 2021-09-16 Аллерган, Инк. 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
KR102880470B1 (ko) 2018-10-23 2025-11-03 다이이찌 산쿄 가부시키가이샤 바이아릴 유도체
CN117018202A (zh) * 2019-07-08 2023-11-10 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
CA3145303A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors
EP4045036A4 (en) 2019-10-16 2023-11-15 ChemoCentryx, Inc. Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
EP4045037A4 (en) 2019-10-16 2023-11-15 ChemoCentryx, Inc. HETEROARYL-BIPHENYL AMINE FOR THE TREATMENT OF PD-L1 DISEASE
IL297675A (en) 2020-04-30 2022-12-01 Idorsia Pharmaceuticals Ltd History of aztidine-3-ylmethanol as ccr6 receptor modulators
KR20240049280A (ko) 2021-08-18 2024-04-16 케모센트릭스, 인크. Ccr6 억제제로서의 아릴 설포닐(하이드록시) 피페리딘
MX2024002173A (es) * 2021-08-18 2024-03-26 Chemocentryx Inc Compuestos de arilsulfonilo como inhibidores de ccr6.
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
JP2024539987A (ja) 2021-10-26 2024-10-31 イドルシア・ファーマシューティカルズ・リミテッド Ｃｃｒ６受容体調節剤
CA3236396A1 (en) 2021-10-28 2023-05-04 Oliver Allemann Ccr6 receptor modulators

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944553A (en) 1974-02-13 1976-03-16 Trw Inc. Bis quinoline peri acids
US4021409A (en) 1975-06-19 1977-05-03 The United States Of America As Represented By The Secretary Of The Air Force Thermally stable benzimidazonaphthyridine compositions
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
WO1991012779A1 (en) 1990-02-28 1991-09-05 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5833651A (en) 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
WO2005113513A2 (en) * 2004-05-12 2005-12-01 Chemocentryx Aryl sulfonamides
DE602006020979D1 (en) * 2005-01-14 2011-05-12 Chemocentryx Inc Heteroarylsulfonamide und ccr2
EA015710B1 (ru) 2006-07-14 2011-10-31 Хемоцентрикс, Инк. Триазолил фенилбензолсульфонамиды
AU2007272972B2 (en) * 2006-07-14 2011-12-01 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides as CCR2 or CCR9 modulators for the treatment of atherosclerosis
WO2009008552A1 (en) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
PL2175859T3 (pl) 2007-07-12 2012-09-28 Chemocentryx Inc Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
ES2554513T3 (es) 2008-05-23 2015-12-21 Novartis Ag Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
JP2012513410A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
WO2011031896A2 (en) 2009-09-09 2011-03-17 Avila Therapeutics, Inc. Pi3 kinase inhibitors and uses thereof
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
EP2549875B1 (en) * 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN103347520A (zh) 2010-10-13 2013-10-09 波士顿大学管理委员会 用作癌症化学治疗的晚期sv40因子（lsf）的抑制剂
KR101985184B1 (ko) 2011-01-28 2019-06-03 주식회사 동진쎄미켐 신규한 유기염료 및 이의 제조방법
TW201311149A (zh) 2011-06-24 2013-03-16 Ishihara Sangyo Kaisha 有害生物防治劑
US9307766B2 (en) 2011-08-25 2016-04-12 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
MX372722B (es) * 2012-02-29 2020-06-19 Chemocentryx Inc Sulfonamidas de aza-aril 1h-pirazol-1-il benceno
AU2014360743C1 (en) 2013-12-02 2021-01-28 Chemocentryx, Inc. CCR6 compounds

Also Published As

Publication number Publication date
EP3076968A4 (en) 2017-04-12
JP6563947B2 (ja) 2019-08-21
IL245704A0 (en) 2016-07-31
CN105960237B (zh) 2020-03-31
IL245704B (en) 2019-10-31
AU2014360743A1 (en) 2016-05-26
EA201691141A1 (ru) 2017-01-30
US9795599B2 (en) 2017-10-24
AU2014360743C1 (en) 2021-01-28
ES2735360T3 (es) 2019-12-18
US20150175547A1 (en) 2015-06-25
US20180092902A1 (en) 2018-04-05
CA2930148A1 (en) 2015-06-11
EP3076968A1 (en) 2016-10-12
CA2930148C (en) 2023-04-11
EA029826B1 (ru) 2018-05-31
CN105960237A (zh) 2016-09-21
US10117865B2 (en) 2018-11-06
US10786494B2 (en) 2020-09-29
JP2016540051A (ja) 2016-12-22
WO2015084842A1 (en) 2015-06-11
US9340509B2 (en) 2016-05-17
EP3076968B1 (en) 2019-04-17
KR102331833B1 (ko) 2021-11-25
US20190167659A1 (en) 2019-06-06
KR20160096634A (ko) 2016-08-16
AU2014360743B2 (en) 2020-07-16
ZA201603167B (en) 2019-09-25
US20160296508A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MD20150091A2 (ro) Compuşi antivirali
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX388170B (es) Polimorfos de selinexor
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
PH12014502032A1 (en) Treatment of brain cancer
MX2016010272A (es) Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo.
MX2015014470A (es) Analogos de combretastatina.
EA201591449A1 (ru) Способы получения противораковых композиций
EA201401045A1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12015502703A1 (en) Pharmaceutical compositions
IN2013MU01219A (es)
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
IN2013CH05394A (es)
IN2014MU00069A (es)
EA201691191A1 (ru) Полиморфные формы n-карбамоилметил-4(r)-фенил-2-пирролидона

Legal Events

Date Code Title Description
FG Grant or registration